Note: This document contains side effect information about infigratinib. Some dosage forms listed on this page may not apply to the brand name Truseltiq.

Applies to infigratinib: oral capsules.

Side effects include:

Most common (≥20%) adverse reactions include nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting.

Most common laboratory abnormalities (≥20%) include increased creatinine, increased phosphate, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased lipase, increased calcium, decreased lymphocytes, decreased sodium, increased triglycerides, increased ALT/AST, increased urate, decreased platelets, decreased leukocytes, decreased albumin, increased bilirubin, and decreased potassium.

For Healthcare Professionals

Applies to infigratinib: oral capsule.

Hematologic

Very common (10% or more): Decreased hemoglobin (53%), decrease lymphocytes (43%), decreased platelets (37%), decreased leukocytes (26%), decreased neutrophils (14%), decreased albumin (24%), increased urate (37%)^[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (32%), pain in extremity (17%)

Common (1% to 10%): Fractures^[Ref]

Ocular

Very common (10% or more): Dry eye (44%), eyelash changes (25%), blurred vision (21%), cataracts (12%)^[Ref]

Metabolic

Very common (10% or more): Increased phosphate (90%), decreased phosphate (64%), increased lipase (44%), increased calcium (43%), decreased sodium (41%), decreased calcium (10%), increased potassium (17%), decreased potassium (21%), decrease weight (15%)^[Ref]

Hepatic

Very common (10% or more): Increased triglycerides (38%), increased alkaline phosphatase (54%), increased alanine aminotransferase (51%), increased cholesterol (18%), increased bilirubin (24%), increased aspartate aminotransferase (38%), increased lipase (44%)^[Ref]

Respiratory

Very common (10% or more): Epistaxis (18%)^[Ref]

Nervous system

Very common (10% or more): Fatigue (44%), dysgeusia (32%)^[Ref]

Renal

Very common (10% or more): Increased creatinine (93%)^[Ref]

Cardiovascular

Very common (10% or more): Edema/peripheral edema (17%)^[Ref]

Dermatologic

Very common (10% or more): Nail toxicity (57%), alopecia (38%), dry skin (23%), palmar-plantar erythrodysesthesia syndrome (33%)^[Ref]

Gastrointestinal

Very common (10% or more): Stomatitis (56), constipation (30%), abdominal pain (26%), dry mouth (25%), diarrhea (24%), vomiting (21%), nausea (19%), dyspepsia (17%)^[Ref]

General

Serious adverse reactions in 2% or more patients included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient. Adverse reactions requiring permanent discontinuation in 1% or more patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.^[Ref]